secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001193125-25-120772
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences Q1 net loss $1.37/share; FB102 celiac data expected, vitiligo trial dosed
--------------------------------------------------------------------------------

- Net loss per share ($1.37) vs ($4.03) YoY; net loss $15.7M on R&D spend of $12.7M.
- Cash $45.9M at March 31, 2025, up from $22.2M at year-end 2024.
- FB102 celiac disease topline data planned for Q2 2025; first vitiligo patient dosed.
- R&D expenses $12.7M (+188% YoY) driven by manufacturing and clinical trial costs.
- Shares outstanding 6.6M plus 4.8M pre-funded warrants as of March 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525120772/0001193125-25-120772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525120772/d818687d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-120772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer